INmune Bio, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $5.4 million, a decrease from the $9.7 million loss recorded in the same period of the previous year. The company did not generate any revenue during this quarter, a significant decline from the $50,000 reported in Q1 2025. Total operating expenses for the quarter were approximately $5.8 million, down from $10 million in the prior year, primarily due to reduced research and development costs associated with the completion of a Phase II trial for its Alzheimer’s program.
The company’s cash and cash equivalents stood at $21.4 million as of March 31, 2026, down from $24.8 million at the end of 2025. Total current assets also decreased to $22.8 million from $29.9 million, while total liabilities fell to $6.2 million from $8.8 million. The reduction in liabilities was attributed to a decrease in accounts payable and accrued liabilities. INmune Bio's accumulated deficit increased to $214.4 million, reflecting ongoing operational losses.
Strategically, INmune Bio is focused on advancing its product candidates, particularly CORDStrom, which is aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The company has completed a pivotal trial for CORDStrom and is preparing for regulatory submissions in the UK and EU, with plans to file a Biologics License Application (BLA) with the FDA in 2026. Additionally, the company has entered into an amended agreement with Anthony Nolan to secure a long-term supply of umbilical cord tissue, which is expected to support the development of CORDStrom and potentially other candidates.
Despite these developments, INmune Bio faces significant challenges, including substantial doubt about its ability to continue as a going concern due to ongoing losses and negative cash flows. The company is exploring various financing strategies, including public or private equity sales, debt financing, and potential collaborations, to secure the necessary funding for its operations. Management has indicated that without sufficient capital, the company may need to delay or scale back its development programs. The outlook remains cautious as the company anticipates continued losses while it seeks to commercialize its product candidates.
About Inmune Bio, Inc.
INmune Bio Inc. develops immunotherapies targeting innate immune dysfunction to treat cancer, neurodegenerative, and inflammatory diseases. Its core platforms include INKmune, an NK cell-based cancer therapy; XPro1595, a TNF inhibitor for Alzheimer's and neuroinflammation; and CORDStrom, a stem cell product for skin disorders. The company focuses on innovative biologics, regulatory pathways, and strategic collaborations to address unmet medical needs in global markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.